Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Business of Medicine

Articles with lock require a GLG News subscription
Posted April 21, 2008
Are physicians who represent plaintiffs any less biased than researchers working with a pharmaceutical company
Analysis of: Reports: Data on Vioxx was misused | www.usatoday.com
Author: GLG Member Program Contributor
The authors of this study obtained the data while representing plaintiffs and their lawyers.Surely they come from a biased viewpoint and perhaps more biased than groups of researchers who have performed a study may not have written all of a final manuscript but had the chance to review it.      ...
Eric Gruff Posted April 21, 2008
Tainted Heparin Will Mean More Scrutiny of Drug Manufacturers
Analysis of: UPDATE: FDA Head Sees Economic Fraud Behind Tainted Heparin | www.reuters.com
Author: Eric Gruff, Principal E4 Consulting
Regardless of the reason (greed, carelessness, incompetence, etc.) that Chinese heparin became tainted, the end result will be increased scrutiny on imported raw materials and other ingredients, not only from China, but from all 3rd World suppliers. How the FDA and other regulatory agencies actually...
Posted April 15, 2008
Big Pharma's future
Analysis of: Where The Jobs Aren’t: Research & Development | www.pharmalot.com
Author: GLG Member Program Contributor
To paraphrase, rumors of big pharma's demise are vastly exaggerated.
Gary Barker Posted April 15, 2008
Novartis grabs a winner
Analysis of: Novartis to buy Nestle's Alcon stakes for $39 billion | www.wtnzfox43.com
Author: Gary Barker, Partner/Owner Eye Associates Of Winter Park
The purchase of a controlling interest in Alcon by Novartis is a brilliant move by Novartis.  To bring the leading contact lens disinfectant together with Ciba's contact lenses is a wonderful marketing opportunity for Ciba.
Posted April 14, 2008
Stem Cell Reseach - A step in the right direction
Analysis of: FDA to take key step in stem cell research | money.cnn.com
Author: GLG Member Program Contributor
Stem cells have a great potential for a wide range of medical treatments.  Laying out the direction to allow for clinical studies is an important step. Cancer Stem cell research is a new area where modulation of stem cell activity may prevent metastatic events.  The FDA's concern for embryonic...
Posted April 14, 2008
Physician owned hospitals. Beneficial to whom? Certainly not the patient!!!
Analysis of: U.S. Reps give boost to physician-owned hospitals | www.fiercehealthcare.com
Author: GLG Member Program Contributor
2 Texas U.S. Reps think that physcian owned hospitals are OK?
Posted April 14, 2008
Not A Big Deal for Glaxo
Analysis of: FDA: Glaxo Failed To Report Avandia Studies | www.pharmalot.com
Author: GLG Member Program Contributor
The infractions cited by the FDA are minor, and the Warning Letter is anything but "harsh."  The implications for Glaxo are likely to be nil, with the exception that the Warning Letter will be used by plaintiffs' attorneys in Avandia-related litigation.
Posted April 14, 2008
Co-Payments for Expensive Drugs Soar: Does Pharma really want governmental controls?
Analysis of: Co-Payments for Expensive Drugs Soar | www.nytimes.com
Author: GLG Member Program Contributor
Co payments which had been $5/10/20 in the past are now a %age of the cost. When the cost may be upwards of $50-100K and you have a 20% co pay you can see the costs that are transfered back to the insured.
Posted April 14, 2008
The Right Decision
Analysis of: Federal Court Sides With GlaxoSmithKline, Strikes Down Rules Issued by Patent Office | biz.yahoo.com
Author: GLG Member Program Contributor
The proposed PTO rules, while logical on the surface, suffer from the all too common defect of over-generalization. In patent applications, as in so many other fields, there is usually not a one size fits all approach.
Posted April 14, 2008
Galaxo's Win is a Win for The Industry
Analysis of: Federal Court Sides With GlaxoSmithKline, Strikes Down Rules Issued by Patent Office | biz.yahoo.com
Author: GLG Member Program Contributor
It often takes several attempts to finalize the Patent Claims and language to satify the examiner.  The limitation of such attempt would place an undue burden on companies and would certainly result in loss of coverage of Intellectual Property (IP). Loss of IP results in reduction of a company...
Previous Page : 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 Next251 to 260 of 649

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-05T05:45:18.353